InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,963.60
(
0.59%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.28
(
-0.16%
)
Bitcoin
57,307.66
(
1.06%
)
Post# of 252525
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119993
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: gdollasign post# 181372

Thursday, 08/21/2014 10:11:17 AM

Thursday, August 21, 2014 10:11:17 AM

Post# of 252525
FMI—In 2Q14, 65% of revenue came from submitting reports directly to treating MDs, and 35% of revenue came from pharma partners. ILMN’s partnership with Big Pharma companies announced today won’t affect the former, but it will likely affect the latter.

As CMS reimbursement kicks in, FMI’s revenue split should move to 85/15 from the current 65/15, which means even less impact from what ILMN is doing with Big Pharma.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up